Zurcher Kantonalbank (Zurich Cantonalbank) Geron Corp Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Geron Corp stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 104,924 shares of GERN stock, worth $395,563. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104,924

Previous 104,924 -0.0%

Holding current value

$395,563

Previous $476,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$3.1 - $5.09 $22,056 - $36,215	7,115 Added 7.27%	104,924 $444,000
Q1 2024 Apr 25, 2024	SELL	$1.75 - $3.44 $9,600 - $18,871	-5,486 Reduced 5.31%	97,809 $322,000
Q4 2023 Jan 30, 2024	SELL	$1.74 - $2.31 $1,266 - $1,681	-728 Reduced 0.7%	103,295 $217,000
Q3 2023 Oct 25, 2023	BUY	$2.11 - $3.28 $35,853 - $55,733	16,992 Added 19.52%	104,023 $220,000
Q2 2023 Aug 07, 2023	BUY	$1.97 - $3.69 $17,418 - $32,626	8,842 Added 11.31%	87,031 $279,000
Q1 2023 May 08, 2023	BUY	$2.14 - $3.4 $21,892 - $34,782	10,230 Added 15.05%	78,189 $169,000
Q4 2022 Feb 01, 2023	BUY	$2.03 - $2.42 $39,505 - $47,095	19,461 Added 40.13%	67,959 $164,000
Q3 2022 Nov 09, 2022	BUY	$1.67 - $2.94 $62,947 - $110,817	37,693 Added 348.85%	48,498 $113,000
Q1 2021 May 03, 2021	BUY	$1.52 - $2.1 $3,027 - $4,183	1,992 Added 22.6%	10,805 $17,000
Q2 2018 Aug 06, 2018	BUY	$3.29 - $4.82 $13,456 - $19,713	4,090 Added 86.6%	8,813 $30,000
Q3 2017 Nov 08, 2017	BUY	$1.99 - $2.65 $9,398 - $12,515	4,723	4,723 $10,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.42B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Geron Corp Transaction History